| This week's sponsor is Precision for Medicine Oncology and Rare Disease.
| 
|
Today's Rundown - AZ, Merck's Lynparza fends off pancreatic cancer, cutting progression risk in half
- Amgen's closely watched KRAS drug, first to clinic, shrinks NSCLC, curbs colorectal tumors
- Astellas, Seattle Genetics' ADC banishes 12% of bladder cancers
- Forget lung cancer history. Merck's Keytruda shatters the stats on long-term survival
- Novartis' Kisqali posts first-in-class survival win in younger women
- Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing
- Merck details Keytruda's second stomach cancer slip
- Sanofi's anti-CD38 combo boosts responses, extends lives in advanced multiple myeloma
- Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval
- Complete response rate in Nektar melanoma trial hits 34%
- In early study results, Grail's blood test identifies 12 cancers before they spread
Featured Story | | | Sunday, June 2, 2019 CHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology annual meeting—and doing it in some of the toughest-to-treat cancers out there. And it wasn’t going to stop this year. |
|
|
 | Thank you to Precision for Medicine Oncology and Rare Disease for sponsoring this week's coverage of ASCO. |
Top Stories Monday, June 3, 2019 CHICAGO—It’s been 30 years in the making, but the first clinical data from a KRAS inhibitor is finally here. In a small phase 1 study, Amgen’s prospect, AMG 510, stopped tumor growth in the majority of patients with non-small cell lung and colorectal cancers. Monday, June 3, 2019 CHICAGO—Astellas and Seattle Genetics unveiled data showing their antibody-drug conjugate shrank 44% of tumors and eliminated 12% of them in patients with advanced urothelial cancer. The treatment could become an option for patients whose cancer has worsened despite receiving chemotherapy and checkpoint inhibitors. Saturday, June 1, 2019 CHICAGO—Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer arena. But Saturday, that’s just what Merck showed its Keytruda could produce. Saturday, June 1, 2019 CHICAGO—Even before it launched, Novartis’ Kisqali was living in the shadow of classmate Ibrance, and it has been ever since. But with its latest data set, Kisqali now has an advantage the Pfizer blockbuster can’t boast. Monday, June 3, 2019 CHICAGO—Blueprint Medicines’ RET inhibitor BLU-667 shrank tumors in 60% of a difficult-to-treat group of lung cancer patients, teeing it up for a 2020 filing in patients with RET-altered non-small cell lung cancer who had already tried chemotherapy. Saturday, June 1, 2019 CHICAGO—Last month, Merck revealed that its Keytruda had run into more trouble in stomach cancer, a disease that’s given it difficulty in the past. And it shared the details of that stumble Saturday. Sunday, June 2, 2019 CHICAGO—Sanofi’s anti-CD38 antibody isatuximab added to the standard of care for relapsed multiple myeloma extended patients’ lives and nearly doubled the number of patients for whom the standard of care worked. Sunday, June 2, 2019 CHICAGO—Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they argue today's new data—showing the drug cut the risk of death by a third—complement the evidence they’ve already generated. Saturday, June 1, 2019 CHICAGO—Nektar Therapeutics has posted updated data on its NKTR-214-Opdivo cocktail in first-line melanoma. The data feature four more complete responses, bringing the rate up 10 percentage points to 34%. Friday, May 31, 2019 CHICAGO—New ASCO data from Grail showed its liquid biopsy test was not only able to detect the presence of 12 different kinds of early-stage cancer but could also identify the disease’s location within the body before it spreads using signatures found in the bloodstream. Resources Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Evidera Discover how healthcare-specific social media can aid researchers in better understanding what matters to patients with rare diseases. Sponsored by: WEGO Health Patient insights and UGC-style content power influencer-driven social media campaigns at scale. Sponsored by: PatientPoint Hear one media expert’s point of view on why every TV investment should be paired with an investment in point of care to truly optimize, and differentiate, your media plan. Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. |
|
